廣告
香港股市 將在 5 小時 57 分鐘 開市
  • 恒指

    16,828.93
    +317.24 (+1.92%)
     
  • 國指

    5,954.62
    +123.36 (+2.12%)
     
  • 上證綜指

    3,021.98
    -22.62 (-0.74%)
     
  • 道指

    38,484.98
    +245.00 (+0.64%)
     
  • 標普 500

    5,069.25
    +58.65 (+1.17%)
     
  • 納指

    15,705.97
    +254.67 (+1.65%)
     
  • Vix指數

    15.80
    -1.14 (-6.73%)
     
  • 富時100

    8,044.81
    +20.94 (+0.26%)
     
  • 紐約期油

    83.39
    +1.49 (+1.82%)
     
  • 金價

    2,338.20
    -8.20 (-0.35%)
     
  • 美元

    7.8354
    -0.0003 (-0.00%)
     
  • 人民幣

    0.9241
    +0.0003 (+0.03%)
     
  • 日圓

    0.0504
    +0.0000 (+0.02%)
     
  • 歐元

    8.3867
    +0.0407 (+0.49%)
     
  • Bitcoin

    66,531.42
    +194.55 (+0.29%)
     
  • CMC Crypto 200

    1,434.16
    +19.40 (+1.37%)
     

Edwards Lifesciences Shares Slide As Q2 Results Miss Expectations, Lowers FY22 Sales Outlook

  • Edwards Lifesciences Corp (NYSE: EW) reported second-quarter sales of $1.37 billion, flat compared to 2Q21, missing the consensus of $1.4 billion.

  • Adjusted EPS was $0.63, which missed the consensus of $0.64.

  • The adjusted gross profit margin was 80.5% for the quarter, compared to 75.9% in 2Q21.

  • Transcatheter aortic valve replacement sales grew to $907 million, up 1%. Globally, the company's average selling price and market position were stable.

  • Surgical Structural Heart sales were $229 million, down 4% Y/Y.

  • EW's cash, cash equivalents, and short-term investments totaled $1.5 billion as of June 30, 2022.

  • 3Q22 Guidance: Edwards Lifesciences expects revenue of $1.30 billion and $1.37 billion (consensus $1.44 billion) and adjusted EPS of $0.58 to $0.66 (consensus $0.65).

  • FY22 Guidance: Edwards Lifesciences expects sales of $5.35 billion to $5.55 billion (prior $5.5 billion - $6.0 billion) vs. consensus of $5.71 billion and adjusted EPS of $2.50 - $2.65 (consensus of $2.56).

  • Price Action: EW shares are trading lower by 5.86% at $101 during the post-market session on Thursday.

  • Photo via Wikimedia Commons

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.